


Epiroprim

Chemical Properties

CAS No. :	73090-70-7
Formula:	C ₁₉ H ₂₃ N ₅ O ₂
Molecular Weight:	353.42
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Epiroprim (Ro11-8958) is a selective dihydrofolate reductase (DHFR) inhibitor with antibacterial activity, inhibiting Staphylococcus, Enterococcus, Pneumococcus, and Streptococcus.
Targets(IC50)	Antibacterial,DHFR
In vitro	The 50% inhibitory concentration (IC50) of Epiroprim against Toxoplasma gondii dihydrofolate reductase was 0.9 μmol. [1] Epiroprim has bactericidal effect with a minimum inhibitory activity of 10 mg/L against Mycobacterium leprae. [3]
In vivo	Epiroprim (300 mg/kg/ day for 14 days, given intraperitoneally) was ineffective against mice acutely infected with the RH strain of Toxoplasma Gondii, but when Epiroprim was combined with oral sulfadiazine (375 mg/kg/ day), a 100% survival rate was seen. [1] Epiroprim (100 mg/kg) combined with dapsone can prevent pneumosporosis and toxoplasmosis in rats. [2]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8295 mL	14.1475 mL	28.2949 mL
5 mM	0.5659 mL	2.8295 mL	5.659 mL
10 mM	0.2829 mL	1.4147 mL	2.8295 mL
50 mM	0.0566 mL	0.2829 mL	0.5659 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Martinez A, et al. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. *Am J Trop Med Hyg.* 1996 Mar;54(3):249-52.

Brun-Pascaud M, et al. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. *Antimicrob Agents Chemother.* 1996 Sep;40(9):2067-70.

Dhople AM. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. *Int J Antimicrob Agents.* 1999 Aug;12(4):319-23.

Mehlhorn H, et al. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models. *Parasitol Res.* 1995;81(4):296-301.

N'guessan K, et al. Etude préliminaire de l'association isoniazide-épiroprim dans un modèle murin de tuberculose [Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model]. *Bull Soc Pathol Exot.* 2002 Nov;95(4):265-8. French.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481